CELLTRION
Celltrion (KRX:068270) announced today that the Defense Logistics Agency (DLA) under the Department of Defense has awarded Celltrion USA, Inc., a subsidiary company of Celltrion, a procurement contract for its DiaTrustTM COVID-19 Ag Rapid Test.
Celltrion USA will make deliveries to approximately 25,000 U.S. CONUS locations to support military bases, long-term care facilities, community testing sites, critical infrastructure, and other designated places on a weekly basis.
The DLA estimates its order volume to be as much as $626 million considering the change in demand by the COVID-19 community transmission rate in the U.S.
Celltrion believes that this procurement contract underscores Celltrion's quality, production and supply capabilities as the deal has been awarded after the Department of Defense’s rigorous verification. Celltrion has already proven the quality and safety of DiaTrustTM earlier this year as the product obtained Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) on April 16. Celltrion’s supply capability for the contract volume is sufficiently supported by the large-scale production facility in Korea. In addition, Celltrion USA emphasized the firm’s drug distribution performance in the US market for the last three years to demonstrate its ability to perform timely deliveries to 25,000 designated places in the U.S., at a competitive price.
Unlike other COVID-19 Antigen Rapid Test kits, DiaTrustTM is a product that applied two antibodies binding COVID-19 virus to both N-protein and S-protein, respectively, resulting in improved sensitivity of 93.3% and specificity of 99.0%. Also, the infection can be diagnosed within only 15 minutes.
The test kits to be supplied through this contact are point-of-care tests (POCT) which can only be used in the presence of medical professionals.
“The fact that we were awarded a procurement contract by the DLA after having passed its strict screen process is a recognition of Celltrion’s technology and supply capability. With the COVID-19 pandemic still not showing signs of waning, we plan to focus on executing this contract as diligently as possible and further solidify the external credibility of Celltrion’s diagnostic test kits portfolio,” said Bonjoong Kim, CEO of Celltrion USA.
About Celltrion, Inc.
Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacturing of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EC’s approval for Inflectra® and Remsima®, respectively, which is the world’s first mAb biosimilar to receive approval from a regulatory agency in a developed country. Also Celltrion received FDA and EC’s approval for Truxima® and Herzuma®. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005328/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CSC Digital Brand Services Announces Integration into CrowdStrike Falcon Adversary Intelligence’s Recon to Accelerate Detection and Enforcement Against Malicious Domains15.9.2025 23:27:00 CEST | Press release
CSC, the world’s leading enterprise-class domain registrar and online brand protection provider, announced today at Fal.Con 2025 a new integration of CSC’s domain security offerings with the CrowdStrike Falcon® cybersecurity platform. The integration with Recon, a core capability within Falcon Adversary Intelligence, enables organizations to accelerate the detection and takedown of malicious domains, reducing exposure to phishing, fraud, and brand abuse. As cybercrime reaches unprecedented levels, adversaries are increasingly exploiting digital assets, brands, and domain name system (DNS) infrastructure. Traditional defenses often overlook domain portfolios, leaving organizations vulnerable to spoofing, impersonation, and account takeovers. CSC and CrowdStrike are uniting to close this gap with a comprehensive solution that integrates advanced threat intelligence, rapid detection, and global enforcement. Through this integration, clients can: Leverage the Recon capability in Falcon Adv
Celonis Debuts at No. 3 on the 2025 Fortune Future 5015.9.2025 22:58:00 CEST | Press release
Celonis, a global leader in Process Mining, today announced it has been named to No. 3 on the 2025 Fortune Future 50 list, recognized among the world’s most promising companies poised for long-term growth. This marks the company’s first appearance on the list alongside a prestigious group of global innovators, and underscores its leadership in enabling successful AI and business transformation through Process Intelligence. Published annually in collaboration with the Boston Consulting Group, the Fortune Future 50 evaluates more than 2,000 public companies to identify those best positioned for sustained growth based on a proprietary system analyzing market potential, innovation, strategy, and investment in the future. “Being named to the Fortune Future 50 is powerful validation of the mission we’ve been on since day one - to make processes work for people, companies and the planet,” said Alex Rinke, co-CEO and co-founder of Celonis. “This is truly just the beginning of seeing how Proces
ElevenLabs-Powered Chroma Awards Opens Call For Submissions, With November 3 Deadline15.9.2025 15:00:00 CEST | Press release
Creator-Led Global AI Film, Music Video, and Games CompetitionUniting the Global AI Creative Community Chroma Awards, a groundbreaking AI Film, Music Video, and Games competition organized by ElevenLabs, the leading AI audio research and product company, announced today that submissions are open for its inaugural competition, with a November 3 deadline. Competition participants can access free trials of AI tools provided by sponsors starting today at https://pack.chromaawards.com/. The Chroma Awards was established with the mission to educate, empower, and spotlight the next generation of artists and showcase how AI can empower human creativity. The competition is organized by ElevenLabs and presented by Google Cloud, Freepik, fal, Dreamina AI, and CapCut. “Through this initiative we hope to unite creators, communities, and companies across the world to bring emerging technology and creative talent together in dialogue,” said Matty Shimura, Chroma Awards. “We’re incredibly grateful to
33 Innovators Join Morgan Stanley Inclusive & Sustainable Ventures Cohort15.9.2025 14:08:00 CEST | Press release
Accelerator’s expanded focus includes sustainable solutions and support for nonprofits 2025 cohort comprised of 33 early-stage innovators from the Americas and EMEA Five-month program to provide founders with $250,000 (£250,000), as well as mentorship and growth resources Morgan Stanley (NYSE: MS) today announced the global cohort of its Inclusive & Sustainable Ventures (MSISV). With founders from the Americas and Europe, the Middle East and Africa (EMEA), the 2025 MSISV cohort will support 29 startups in its Lab and four emerging nonprofits in its Collaborative, two in-house accelerators that will run over the next five months. Selected from thousands of applications, the 33 organizations will engage in a tailored entrepreneurship curriculum and receive mentorship and business-growth resources from Morgan Stanley’s ecosystem of internal and external partners. The firm will invest $250,000 (£250,000 in EMEA) in each startup and provide each nonprofit with a $250,000 grant. “Morgan Stan
Helmholtz Munich and Parse Biosciences GigaLab Generate World’s Largest Human Lung Tissue Perturbation Atlas15.9.2025 14:00:00 CEST | Press release
Researchers aim to identify cellular circuit mechanisms and generate a dataset to fuel AI-driven foundational research of lung biology Helmholtz Munich and Parse Biosciences today announced a strategic partnership to generate the world’s broadest lung disease perturbation atlas, powered by Parse Biosciences’ GigaLab platform. Using a human lung ex-vivo tissue slice culture model from normal control donor lungs as well as explant lung tissues from patients with chronic lung disease, the study aims to identify novel targets and cell circuits in lung health and disease by characterizing disease-specific responses of cells to 900 pharmacological interventions. Prof Herbert Schiller, Director of Helmholtz Munich’s Precision Regenerative Medicine Research Unit, and a leading researcher on lung biology and disease, will head this ambitious initiative. “Measuring the effects of drug treatments at single cell level directly in human lung tissue at scale, will help us to find strategies that imp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom